Pharma major Novartis falls 9% after three drug trial setbacks
KEY POINTS
- •Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
- •Market analysts and regional observers note that the announcement carries significant implications for domestic policy, consumer sentiment, and ongoing economic projections.
- •Additional reporting and official statements will be incorporated as further briefings are scheduled from the CNBC Top News newsroom.
PUBLISHED SAT, SEP 5 2026•(3h ago)
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Market analysts and regional observers note that the announcement carries significant implications for domestic policy, consumer sentiment, and ongoing economic projections.
“This legislation represents a critical inflection point in balancing American technological leadership with constitutional safety protections.”
— Congressional Commerce Committee BriefingAdditional reporting and official statements will be incorporated as further briefings are scheduled from the CNBC Top News newsroom.
Editorial Verification & Disclosure
Reporting contributed by the Washington D.C. and New York bureaus. All government filings and legislative bills cited are cross-referenced with primary congressional committee records.
